Innovative multilayer nanocarriers (e.g., core-shell micelles) achieve efficient and stable co-encapsulation of hydrophilic, hydrophobic, and nucleic acid loads within a single carrier.
Targeting Delivery for Combination Therapy
Combination therapy is the mainstream approach for complex diseases, leveraging multiple mechanisms to achieve synergy and overcome drug resistance. Optimal efficacy requires the simultaneous, efficient delivery of diverse agents to the lesion. Creative Biolabs' targeted delivery technology focuses on the engineering of multifunctional nanocarriers to achieve co-encapsulation, synergistic release, and environmentally triggered on-demand activation of multiple payloads.
Click Here to View more about our Service
What is Targeted Delivery?
In combination therapy, "targeted delivery" is the core strategy for maximizing efficacy. It refers to:
Multi-load Synergistic Encapsulation: Simultaneously and stably encapsulating two or more loads with different physicochemical properties (e.g., small molecule chemotherapy drug + siRNA, photosensitizer + immune adjuvant) within a single nanocarrier.
Synchronous/Sequential Release: The carrier must be able to achieve synchronous release of the load at the target site to achieve maximum synergy, or sequential release to optimize the treatment process, according to therapeutic needs.
Overcoming Drug Resistance: Improving therapeutic efficacy by delivering drug resistance reversal agents (such as P-gp inhibitors or related genes) in synergy with the main chemotherapy drugs, physically bypassing the cellular efflux pumps.
Applications for Combination Therapy
Targeted delivery systems offer transformative potential across multiple therapeutic areas:
Tumor Drug Resistance Reversal
Delivering chemotherapy drugs and siRNA that knocks down drug resistance genes (such as MDR1), synergistically released within tumor cells, restoring cellular sensitivity to chemotherapy drugs.
Multimodal Cancer Therapy
Delivering photosensitizers and immunomodulatory molecules/adjuvants, achieving systemic anti-tumor immunity through PDT-induced immunogenic cell death (ICD) combined with immunomodulation.
Targeting Angiogenesis and Tumor Cells
Dual-Targeting Combination: Delivering angiogenesis inhibitors to disrupt tumor blood vessels, while simultaneously delivering cytotoxic drugs to kill tumor cells for a coordinated attack.
Anti-infection & Chronic Disease Treatment
Antibiotic-Gene Combination: Delivering antibiotics and drug resistance gene inhibitors to overcome bacterial resistance, mitigating the global threat of antimicrobial resistance.
Fig.1 Combinatorial therapy and nanoparticle-codelivery therapy strategies for human diseases.1
Delivery Challenges of Combination Therapy
- Multi-payload Compatibility & Encapsulation Efficiency: Payloads (e.g., hydrophilic small molecules, hydrophobic proteins, and nucleic acids) have significantly different physicochemical properties, making it difficult to achieve highly efficient and stable synergistic co-encapsulation within a single vector.
- Precise Release Kinetic Control: The vector must ensure that both payloads are released simultaneously or sequentially at the target site in the optimal ratio and time to maximize synergistic effects; otherwise, the combination may fail.
- Vector Complexity & Safety: The design of multifunctional vectors is inherently complex, often leading to significant batch-to-batch variations and increasing the risk of in vivo immunogenicity and toxicity. The crucial intracellular barrier (endosomal/lysosomal entrapment) often degrades payloads before release, severely limiting efficacy.
What We Can Offer
We offer professional targeted delivery technologies, focusing on solving the challenges of synergistic encapsulation, release control, and stability in combination therapies:
Multi-load Co-Encapsulation Platform
Microenvironment-Responsive Release
We design carriers sensitive to internal stimuli (pH, enzyme, reduction) to achieve precise synchronous or sequential release in the tumor microenvironment, ensuring optimal synergistic effects.
Anti-Drug Resistance Nanocarriers
Specializing in encapsulating siRNA or gene editing tools to knock down drug-resistant genes and synergistically deliver chemotherapy drugs, effectively reversing tumor multidrug resistance.
CMC Optimization and Stability
We provide comprehensive CMC support, leveraging our modular assembly platform to guarantee batch-to-batch stability and accelerate clinical translation by reducing immunogenicity risks. Our Engineered Endosomal Escape (E-Esc) technology ensures payload bioavailability.
Why Choose Us?
Guaranteed Synergistic Ratio
Our controlled loading and release technology ensures the precise stoichiometric ratio is maintained from injection to cellular delivery.
MDR Reversal Expertise
We specialize in co-delivering chemosensitizers and gene modulators to overcome cancer drug resistance.
Accelerated Development
The proprietary Modular Assembly Platform de-risks and accelerates the formulation and scale-up of complex nanocarriers.
Efficacy Assurance
Our E-Esc technology maximizes payload bioavailability by preventing premature lysosomal degradation.
Workflow
Unlock your synergistic combination therapies with targeted delivery technology! Your combination therapies need to overcome the challenges of multi-payload compatibility and synergistic release. Please contact our team of delivery experts for customized multifunctional nanocarriers and release kinetics optimization solutions.
Reference
- Li, Xiaotong, et al. "Multifunctional nanoparticle-mediated combining therapy for human diseases." Signal Transduction and Targeted Therapy 9.1 (2024): 1. Distributed under Open Access license CC BY 3.0, without modification. https://doi.org/10.1038/s41392-023-01668-1
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
